CASE STUDY ON BETA BLOCKERS INDUCED PSORIASIS
DOI:
https://doi.org/10.22159/ijpps.2019v11i3.29388Keywords:
Beta blockers, Clinical Pharmacist, Drug induced, Erythematous lesions, HypertensionAbstract
Drug-induced Psoriasis is one among the common etiological factors of Psoriasis reported worldwide. Familiar drugs known to cause psoriasiform eruptions include Anti-malarials, Beta blockers, NSAIDs, Lithium. etc. Certain antihypertensives like ACE inhibitors, diuretics are also documented to have caused psoriatic episodes.
A 57 y old South-Indian male patient with a history of Hypertension, Diabetes Mellitus, Atrial Fibrillation for 4 y; was on antihypertensive therapy for Hypertension and Atrial Fibrillation with proponolol for past 2 y and metoprolol initially. He was presented to the hospital two weeks after switching on to Metoprolol therapy for chief complaints of erythematous scaly lesions especially over both the extremities and paronydrial appearance of nails. Initially, he was on Propranolol therapy which was then shifted to Metoprolol due to an appearance of oral lesions in the mouth. Metoprolol was now discontinued and switched on to Atenolol. After 1-2 w of therapy with Atenolol, the lesions were found to disappear and no recurrence of psoriatic conditions were found.
Proper reviewing of medical history for any allergic reactions and the optimization of drug therapy through Therapeutic Drug Monitoring could be initiated by Clinical Pharmacist in order to avoid such drug-induced flares.
Downloads
References
Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halvey S. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venerol 2005;85:299-30.
Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 2010;49:1351-61.
Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007;25:606-15.
Coulter DM, Pillans PI. Angiotensin-converting enzyme inhibitors and psoriasis. N Z Med J 1993;106:392-3.
Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica 1990;181:51-3.
Gilleaudeau P, Vallat VP, Carter DM, Gottileb AB. Angiotensin-converting inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 1993;28:490-2.
Stavropoulos PG, Kostakis PG, Papakonstantinou AM, Panagiotopoulos A, Petridis AD. Coexistence of psoriasis and pemphigus after enalapril intake. Dermatology 2003;207:336-7.
Antonov D, Grozdev I, Pehlivanov G, Tsankov N. Psoriatic erythroderma associated with enalapril. Skinmed 2006;5:90-2.
Thakor P, Padmanabhan M, Johnson A, Pararajasingam T, Thakor S, Jorgensen W. Ramipril-induced generalized pustular psoriasis: case report and literature review. Am J Ther 2010;17:92-5.
Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch Dermatol 1980;116:902-5.
Burrell HE, Simpson AW, Mehat S, McCreavy DT, Durham B, Fraser WD, et al. Potentiation of ATP-and bradykinin-induced [Ca2+]c responses by PTHrP peptides in the HaCat cell line. J Invest Dermatol 2008;128:1107-15.
Kawamura A, Ochiai T. Candesartan cilexetil induced pustular psoriasis. Eur J Dermatol 2003;13:406-7.
Weger W, Hofer A, Wolf P, EI-Shabrawi Y, Renner W, Kerl H, Salmhofer W. The angiotensin-converting enzyme insertion/deletion and the endothelin-134 3A/4A gene polymorphisms in patients with chronic plaque psoriasis. Exp Dermatol 2007;16:993-8.
Cheng H, Li Y, Zuo XB, Tang HY, Tang XF, Gao JP, et al. Identification of a missense variant in LNPEP that confers psoriasis risk. J Invest Dermatol 2014;134:359-65.
Huskic J, Alender F. Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis. Bosn J Basic Med Sci 2007;7:103-6.
Cruickshank JM, Prichard N. Beta-adrenoceptors. In: Cruickshank JM, Prichard N. (ed). Beta blockers in clinical practice London: Churchill Livingstone; 1996. p. 9-86.
Raychaudhuri S, Farber E. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venerol 2001;15:16-7PMID:11451313.
Cochran RE, Thomson J, Fleming K, Mcqueen A. The psoriasiform eruption induced by practolol. J Cutan Path 1975;2:314-9.
Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exper Dermatol 2001;26:314-20.
Peterson LA. Reactive metabolites in the biotransformation of molecules containing a furan ring. Chem Res Toxicol 2013;26:6-25.
Wu S, Han J, Li WQ. hypertension, antihypertensive medication use and risk of psoriasis. JAMA Dermatol 2014;150:957-63.
Abel EA, Dicicco LM, Orenberg EK. drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986;15:1007-22.
Marshall RJ, Jackson RT. Analysis of case cross over designs. Stat Med 1993;12:2333-41.
Halevy S, Livni E. Beta-adrenergic blocking drugs and psoriasis: the role of an immunologic mechanism. J Am Acad Dermatol 1993;29:504-5.
Maclure M. The case cross over design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-53.
Laskar IJ, Pinaki C, Babul D. Toxic epidermal necrolysis induced by carbamazepine. A Case Study; AJPCR, 2017;10:78-81.
Gupta AK, Pandey SS, Pandey BL. Pharmacovigilance in 150 cases of plaque psoriasis and a case for conventional therapy. Asian J Pharm Clin Res 2012:5:87-9.
